Helex

Others · BioTech · Seed

Programmable lipid nanoparticle (LNP) genetic medicines and targeted gene therapies

About

Helex is a deeptech biotechnology startup developing non-viral, targeted genomic medicines using proprietary Lipid Nanoparticle (LNP) delivery platforms and CRISPR-based precision gene-editing designs. The company's pipeline focuses on first-in-class, disease-modifying therapies for severe unmet clinical needs, including Autosomal Dominant Polycystic Kidney Disease (ADPKD) and chronic kidney diseases.

Founded

May 2021

Total Funding

$3.5M

Key Investors

pi Ventures, Bluehill Capital, SOSV (IndieBio), Bayer Co.Lab

Core Innovation

Kidney-targeted programmable LNP delivery platform and computational gRNA precision engine

Primary Indication Focus

Autosomal Dominant Polycystic Kidney Disease (ADPKD) & Chronic Kidney Diseases

Legal Entity (India)

GENOHELEX CARE PRIVATE LIMITED (CIN: U85300TG2021PTC151736)

Incubation Support

ASPIRE-BioNEST (University of Hyderabad), Bayer Co.Lab, IndieBio

Team

Dr. Poulami Chaudhuri(Co-founder & CEO)

Rohini Kalvakuntla(Co-founder & CBO)

Anirudh Nishtala(Co-founder & COO)

Office

Directions

5F Dalhousie Towers, Hill County Apartments, Nizampet Road, Bachupally, Quthbullapur, Hyderabad, Telangana 500090

loading map pinpoint…